Over the next six months, the US Food and Drug Administration (FDA) is widely anticipated to approve a trio of monoclonal antibody (mAb) drugs for preventing migraine, in what could be a new era in the disease’s treatment…

Para acessar a publicação na íntegra clique aqui

Fonte: NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 3 MARCH 2018 207